Wayshine Biopharm, Inc.
Clinical trials sponsored by Wayshine Biopharm, Inc., explained in plain language.
-
New hope for lung cancer patients whose tumors outsmart frontline therapy
Disease control Recruiting nowThis study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The main goal is to see how many patients' tumors shrink or …
Phase: PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated May 17, 2026 03:29 UTC
-
New drug combo shows promise for tough lung cancers
Disease control Recruiting nowThis study tests a new drug (WSD0922-FU) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). The goal is to see if the combination is safe and can shrink tumors or slow th…
Phase: PHASE1, PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC